New HCV Treatment Paradigms — Now Also for Patients with HIV

In a preliminary analysis presented at CROI 2011, the addition of telaprevir to standard HCV regimens was tolerable and associated with a remarkable improvement in coinfected patients.

This year, we will witness a major paradigm shift in the treatment of hepatitis C virus (HCV) infection. The protease inhibitors boceprevir and telaprevir — the first of many antiviral drugs that target various steps of the HCV life cycle — are expected to be approved this summer. These drugs have been shown to almost double treatment response rates for HCV-monoinfected patients. However, until CROI 2011, all the reported clinical studies had specifically excluded patients with HIV coinfection, even though these patients have a more pressing need for better treatments and greater potential for drug interactions.

Rudolph van Heeswijk and Edward O'Mara presented the first studies to date of potential interactions among boceprevir, telaprevir, …

Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

New HCV Treatment Paradigms — Now Also for Patients with HIV

Topics

Author